Anzeige
Mehr »
Login
Donnerstag, 14.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Investment in die Zukunft: Absoluter Geheimtipp - diese Aktie beschleunigt deine Renditechancen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14UAW | ISIN: SE0007045414 | Ticker-Symbol: 5J3
Frankfurt
14.11.24
09:16 Uhr
0,019 Euro
+0,008
+70,18 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
SCIBASE HOLDING AB Chart 1 Jahr
5-Tage-Chart
SCIBASE HOLDING AB 5-Tage-Chart
PR Newswire
174 Leser
Artikel bewerten:
(1)

SciBase: Interim report January 1 - September 30, 2024

Finanznachrichten News

STOCKHOLM, Nov. 12, 2024 /PRNewswire/ -- January 1 - September 30, 2024

The third quarter in figures

  • Net sales were TSEK 8,408 (7,248), +16%.
  • The loss after tax was TSEK 17,753 (12,786).
  • The loss per share was SEK 0.08 (0.11).
  • The cash flow from current operations was negative in the amount of TSEK 16,745 (17,827).
  • The gross margin was 75.7% (68.2%).
  • Electrode sales volume increased by 2% and was 17,210 (16,922) units. Repeat sales of electrodes to existing customers decreased by 7% as Q3-23 included large electrode orders prior to a price increase.

January - September in figures

  • Net sales were TSEK 21,107 (17,481), +21%.
  • The loss after tax was TSEK 43,663 (35,044).
  • The loss per share was SEK 0.27 (0.34).
  • The cash flow from current operations was negative in the amount of TSEK 44,835 (34,633).
  • The gross margin was 72.0% (67.5%).
  • Electrode sales volume increased by 13% and was 45,078 (39,866) units. Repeat sales of electrodes to existing customers increased by 10%.

Important events during the quarter

  • Overall sales increased by 16% (+17, before currency effects). Sales in Germany within the skin cancer segment decreased by 8% (6% in local currency) following some customers building up inventory in Q3-23. Sales in the US skin cancer market increased by 187% while the sales within the skin barrier segment increased by 102%.
  • In the US a Consensus report by leading US clinicians assessing technologies for melanoma detection and management was published. The report concluded that the Nevisense AI-driven technology can significantly enhance early melanoma detection.
  • The National Institutes of Health (NIH), one of the world's foremost medical research centers and a part of the U.S. Department of Health and Human Services, purchased Nevisense for research on the skin barrier. This sale represents a major milestone for SciBase and demonstrates the high quality and innovative nature of Nevisense for research in this area.
  • SciBase continued to expand in the US with new customers in new regions.
  • SciBase announced the change of Certified Adviser from Vator Securities to Carnegie Investment Bank AB (publ).

Important events after the end of the period

  • A Nomination Committee has been appointed for SciBase Holding's Annual General Meeting in 2025.
  • SciBase initiates sales collaboration in Italy.
  • SciBase decides on a directed issue of approximately SEK 22.5 million and a rights issue of up to approximately SEK 59.3 million.





Oct 1, 2023 -



July 1 - Sep 30

Jan 1 - Sep 30

Sep 30, 2024

Jan 1 - Dec 31

THE GROUP

2024

2023

2024

2023

Rolling-12

2023

Net sales, SEK ths

8 408

7 248

21 107

17 481

26 870

23 245

Gross margin, %

75,7 %

68,2 %

72,0 %

67,5 %

72,3 %

69,0 %

Equity/Asset ratio, %

67,6 %

72,4 %

67,6 %

72,4 %

70,4 %

66,9 %

Net indebtness, multiple

0,48

0,38

0,48

0,38

0,42

0,49

Cash equivalents, SEK ths

24 714

52 353

24 714

52 353

24 714

34 121

Cashflow from operating activities, SEK ths

-16 475

-17 827

-44 835

-34 633

-62 187

-51 984

Earnings per share (before and after dilution), SEK

-0,08

-0,11

-0,27

-0,34

-0,42

-0,51

Shareholder's equity per share, SEK

0,17

0,50

0,23

0,58

0,32

0,40

Average number of shares, 000'

219 538

119 831

164 146

104 029

153 067

107 980

Number of shares at closing of period, 000'*

219 538

119 831

219 538

119 831

219 538

119 831

Share price at end of period, SEK

0,48

1,24

0,51

1,24

0,51

0,83

Number of sold electrodes, pieces

17 210

16 922

45 078

39 866

57 132

51 920

Average number of employees

29

23

27

22

27

23

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on November 12, 2024.

This report has been comprehensively reviewed by the Company's auditors.

For additional information, please contact:
Pia Renaudin, CEO, tel. +46732069802, e-mail: pia.renaudin@scibase.com

Certified Advisor (CA):

Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: certifiedadviser@carnegie.se

About SciBase
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/scibase/r/interim-report-january-1---september-30--2024,c4064790

The following files are available for download:

https://mb.cision.com/Main/12371/4064790/3107201.pdf

Interim report Q3 2024 - final

Cision View original content:https://www.prnewswire.co.uk/news-releases/scibase-interim-report-january-1--september-30-2024-302302262.html

© 2024 PR Newswire
5 heiße Wetten für den Jahresendspurt!
Nach dem unerwartet schnellen Ende der US-Wahlen mit dem Sieg des republikanischen Kandidaten Donald Trump fackelten die Aktien- und Krypto- Märkte ein wahres Kursfeuerwerk ab und bliesen zur Jahresendrallye.

Im aktuellen kostenlosen Report beleuchten wir 5 aussichtsreiche Unternehmen, die das Fundament besitzen, in den nächsten Monaten den breiten Markt zu schlagen.

Seien Sie dabei!

Fordern Sie jetzt unseren brandneuen neuen Spezialreport an und erfahren Sie, welche Aktien aufgrund ihrer Bewertung sowie charttechnischen Situation das Potenzial zu einer Outperformance besitzen.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.